This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Peijia Medical Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Yi Zhang

Chief Executive Officer (CEO)

CN¥1.5m

Compensación total

Porcentaje del salario del CEO	50.7%
Permanencia del CEO	12.3yrs
Participación del CEO	0.8%
Permanencia media de la dirección	4.9yrs
Promedio de permanencia en la Junta Directiva	4.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Yi Zhang en comparación con los beneficios de Peijia Medical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CN¥252m
Mar 31 2024	n/a	n/a	-CN¥322m
Dec 31 2023	CN¥1m	CN¥740k	-CN¥393m
Sep 30 2023	n/a	n/a	-CN¥460m
Jun 30 2023	n/a	n/a	-CN¥528m
Mar 31 2023	n/a	n/a	-CN¥468m
Dec 31 2022	CN¥1m	CN¥1m	-CN¥408m
Sep 30 2022	n/a	n/a	-CN¥449m
Jun 30 2022	n/a	n/a	-CN¥491m
Mar 31 2022	n/a	n/a	-CN¥533m
Dec 31 2021	CN¥2m	CN¥1m	-CN¥574m

Compensación vs. Mercado: La compensación total de Yi($USD205.33K) está por debajo de la media de empresas de tamaño similar en el mercado Hong Kong ($USD349.51K).

Compensación vs. Ingresos: La compensación de Yi ha aumentado mientras la empresa no es rentable.

CEO

Yi Zhang (56 yo)

12.3yrs

Permanencia

CN¥1,460,000

Compensación

Dr. Yi Zhang has been an Executive Director of Peijia Medical Limited since May 30, 2012. He serves as the Chairman and Chief Executive Officer at Peijia Medical Limited and served as its Chief Technology...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Yi Zhang	Chairman & CEO	no data	CN¥1.46m	0.77% HK$ 14.8m
Leo Tsai	Chief Financial Officer	5.4yrs	sin datos	sin datos
Kongrong Pan	Chief Operating Officer	7.1yrs	sin datos	sin datos
Fong Tan Jian	Chief Technology Officer	3.7yrs	sin datos	sin datos
Ping Ye Zhang	Executive Director	4.7yrs	CN¥182.00k	0.15% HK$ 2.9m
Hong Ye	Executive Director & Company Secretary	11.9yrs	CN¥1.36m	2.02% HK$ 38.5m
Xiaoxiao Zhuang	Vice President of Sales	4.4yrs	sin datos	sin datos
Hongpeng Wang	Vice President of Marketing	5.2yrs	sin datos	sin datos
Hing Ling Chau	Company Secretary	2.3yrs	sin datos	sin datos

4.9yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 9996 se considera experimentado (4.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yi Zhang	Chairman & CEO	12.3yrs	CN¥1.46m	0.77% HK$ 14.8m
Ping Ye Zhang	Executive Director	6.1yrs	CN¥182.00k	0.15% HK$ 2.9m
Hong Ye	Executive Director & Company Secretary	11.9yrs	CN¥1.36m	2.02% HK$ 38.5m
Stephen Newman Oesterle	Independent Non-Executive Director	4.7yrs	CN¥1.55m	sin datos
Huacheng Wei	Independent Non-Executive Director	3yrs	CN¥315.00k	sin datos
Wai Ming Yip	Independent Non-Executive Director	4.7yrs	CN¥314.00k	sin datos
Fei Chen	Non-Executive Director	5.3yrs	sin datos	sin datos
Robert Parks	Independent Non-Executive Director	4.7yrs	CN¥1.55m	sin datos
Zhiyun Yu	Non-Executive Director	8.5yrs	sin datos	sin datos
Jifeng Guan	Non-Executive Director	4.9yrs	sin datos	sin datos
Jun Yang	Non-Executive Director	4.1yrs	sin datos	sin datos

4.9yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de 9996 se considera experimentada (4.9 años de antigüedad promedio).

This company listing is no longer active

Peijia Medical Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

Less than half of directors are independent

Executive Director & Company Secretary recently sold HK$3.1m worth of stock

Less than half of directors are independent

Peijia Medical Limited Announces Executive Changes

Peijia Medical Limited, Annual General Meeting, Jun 10, 2022

Recent updates

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Peijia Medical Limited to Report First Half, 2024 Results on Aug 23, 2024

Full year 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.61 loss in FY 2022)

Less than half of directors are independent

Peijia Medical Limited to Report Fiscal Year 2023 Results on Jun 15, 2024

Full year 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.61 loss in FY 2022)

Peijia Medical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Forecast to breakeven in 2025

Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial

Forecast to breakeven in 2025

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

Peijia Medical Limited to Report First Half, 2023 Results on Aug 31, 2023

Now 22% undervalued after recent price drop

Peijia Medical Limited Announces First Patient in Multi-Center Registration Clinical Trial of Taurustrio™? Transcatheter Aortic Valve Replacement System in China

Peijia Medical Limited Provides Unaudited Revenue Guidance for the Period from January 1, 2023 to June 30, 2023

New minor risk - Profitability

Peijia Medical Limited Receives Approval from the National Medical Products Administration of the PRC for the Registration Application of DCwireTM Micro Guidewire

Executive Director & Company Secretary recently sold HK$3.1m worth of stock

Forecast to breakeven in 2025

Peijia Medical Limited Announces First Patient Enrollment in the Multi-Center Registration Clinical Trial of Geminione Transcatheter Edge-To-Edge Repair System in China

Peijia Medical Limited Announces in Partnership with inQB8 Medical Technologies, LLC Successfully Completed the First Patient Implant in the First-In-Man Clinical Trial of the MonarQ Transcatheter Tricuspid Valve Replacement System in the World

Less than half of directors are independent

Peijia Medical Limited Announces First Patient Implant in Multi-Center Registrationclinical Trial of Peijia Highlife Transcatheter Mitralvalve Replacement System in China

First half 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 loss in 1H 2021)

Peijia Medical Limited to Report First Half, 2022 Results on Aug 19, 2022

Forecast to breakeven in 2024

Peijia Medical Limited Announces Executive Changes

Peijia Medical Limited Receives NMPA Approval for Registration Application of Fluxcap Balloon Guide Catheter

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC for the Registration Application of Tethys AS Aspiration Catheter

Peijia Medical Limited, Annual General Meeting, Jun 10, 2022

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.86 loss per share (vs CN¥4.43 loss in FY 2020)

Peijia Medical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Peijia Medical Limited Receives the Approval from the National Medical Products Administration for Syphonet® Stent Retriever

Peijia Medical Limited Announces First Patient Implant in Research Clinical Trial of Peijia's Highlife Trans-Septal Mitral Valve Replacement System in China

Peijia Medical Announces First Patient Implant in the Clinical Trial of Its Third-Generation Transcatheter Aortic Valve System TaurusNXT

Peijia Medical Limited Announces First Patient Implant in Clinical Trial of TaurusNXT

First half 2021 earnings released: CN¥0.27 loss per share (vs CN¥8.68 loss in 1H 2020)

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC of the Registration Application for TaurusElite

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.33 loss in FY 2019)

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.26 loss in FY 2019)

Peijia Medical Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Peijia Medical Limited Announces Patient Enrollment for the Clinical Trial Ofshenyi Stent Retriever

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad